Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells

(1) Background: TP53 deficiency remains a major adverse event in Multiple Myeloma (MM) despite therapeutic progresses. As it is not possible to target TP53 deficiency with pharmacological agents, we explored the possibility of activating another p53 family member, p73, which has not been well studie...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Mol Sci
Egile Nagusiak: Gillardin, Pierre-Samuel, Descamps, Géraldine, Maiga, Sophie, Tessoulin, Benoit, Djamai, Hanane, Lucani, Benedetta, Chiron, David, Moreau, Philippe, Le Gouill, Steven, Amiot, Martine, Pellat-Deceunynck, Catherine, Moreau-Aubry, Agnès
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2017
Gaiak:
Brief Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5795990/
https://ncbi.nlm.nih.gov/pubmed/29295500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19010040
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak